Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: A genome-wide association study

Research output: Contribution to journalArticlepeer-review

152 Scopus citations

Abstract

IMPORTANCE: Because APOE locus variants contribute to risk of late-onset Alzheimer disease (LOAD) and to differences in age at onset (AAO), it is important to know whether other established LOAD risk loci also affect AAO in affected participants. OBJECTIVES To investigate the effects of known Alzheimer disease risk loci in modifying AAO and to estimate their cumulative effect on AAO variation using data from genome-wide association studies in the Alzheimer Disease Genetics Consortium. DESIGN, SETTING, AND PARTICIPANTS: The Alzheimer Disease Genetics Consortium comprises 14 case-control, prospective, and family-based data sets with data on 9162 participants of white race/ethnicity with Alzheimer disease occurring after age 60 years who also had complete AAO information, gathered between 1989 and 2011 at multiple sites by participating studies. Data on genotyped or imputed single-nucleotide polymorphisms most significantly associated with risk at 10 confirmed LOAD loci were examined in linear modeling of AAO, and individual data set results were combined using a random-effects, inverse variance-weighted meta-analysis approach to determine whether they contribute to variation in AAO. Aggregate effects of all risk loci on AAO were examined in a burden analysis using genotype scores weighted by risk effect sizes. MAIN OUTCOMES AND MEASURES: Age at disease onset abstracted from medical records among participants with LOAD diagnosed per standard criteria. RESULTS: Analysis confirmed the association of APOE with earlier AAO (P = 3.3 × 10-96), with associations in CR1 (rs6701713, P = 7.2 × 10-4), BIN1 (rs7561528, P = 4.8 × 10-4), and PICALM (rs561655, P = 2.2 × 10-3) reaching statistical significance (P < .005). Risk alleles individually reduced AAO by 3 to 6 months. Burden analyses demonstrated that APOE contributes to 3.7%of the variation in AAO (R2 = 0.256) over baseline (R2 = 0.221), whereas the other 9 loci together contribute to 2.2%of the variation (R2 = 0.242). CONCLUSIONS AND RELEVANCE: We confirmed an association of APOE (OMIM 107741) variants with AAO among affected participants with LOAD and observed novel associations of CR1 (OMIM 120620), BIN1 (OMIM 601248), and PICALM (OMIM 603025) with AAO. In contrast to earlier hypothetical modeling, we show that the combined effects of Alzheimer disease risk variants on AAO are on the scale of, but do not exceed, the APOE effect. While the aggregate effects of risk loci on AAO may be significant, additional genetic contributions to AAO are individually likely to be small.

Original languageEnglish
Pages (from-to)1394-1404
Number of pages11
JournalJAMA Neurology
Volume71
Issue number11
DOIs
StatePublished - Nov 1 2014

Bibliographical note

Publisher Copyright:
Copyright 2014 American Medical Association. All rights reserved.

Funding

FundersFunder number
Alzheimer's AssociationIIRG-05-14147, IIRG-08-89720
Coins for Alzheimer's Research Trust
AstraZeneca
Boston University School of Public Health/Boston University Medical CampusP30 AG013846, U01 AG10483, R01 AG017173, R01 MH080295, R01AG33193, R01 AG025259, R01 CA129769
Bristol-Myers Squibb
Canadian Institutes of Health Research
Columbia UniversityP50 AG008702, R37 AG015473
Charles A Dana Foundation
Duke-Kunshan UniversityAG05128, P30 AG028377
Eli Lilly and Company
University Research Committee, Emory UniversityAG025688
GE Healthcare
Genentech Incorporated
GlaxoSmithKline
Higher Education Funding Council for England
Howard Hughes Medical Institute
University of Southern IndianaP30 AG10133
Johnson and Johnson Pharmaceutical Research and Development
Massachusetts General HospitalP50 AG005134
Mayo Clinic RochesterP50 AG016574
Medical Research Council
National Institute of Biomedical Imaging and Bioengineering
National Institute of Mental HealthMH60451
Institute of Neurological Disorders and Stroke National Advisory Neurological Disorders and Stroke CouncilNS39764
National Institute on AgingRC2 AG036535, AG034504, U01 AG024904, K01 AG030514
York University, New York, New York, USA bbbUniversity of Rochester, Rochester, New YorkUL1 RR029893, P30 AG08051, 1RC2AG036502, 5R01AG012101, MO1RR00096, 5R01AG022374, 1R01AG035137, 5R01AG013616
Newcastle University
Northwestern Polytechnical UniversityP30 AG013854
Biomedical Laboratory Research and Development, VA Office of Research and Development
Oregon Health and Science UniversityP30 AG008017, R01 AG026916
Pfizer
Schering Plough Co
Stichting MS Research
University of California, Los AngelesP50 AG016570
Miami Clinical and Translational Science Institute, University of MiamiAG027944, AG021547, R01 AG027944, AG010491, AG019757
University of Southern CaliforniaP50 AG005142
Vanderbilt Digestive Diseases Research Center, Vanderbilt University Medical CenterR01 AG019085
Wellcome Trust
National Center for Advancing Translational Sciences (NCATS)UL1TR000135
National Center for Advancing Translational Sciences (NCATS)

    ASJC Scopus subject areas

    • Clinical Neurology

    Fingerprint

    Dive into the research topics of 'Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: A genome-wide association study'. Together they form a unique fingerprint.

    Cite this